Equality Diversity & Inclusion

We will focus on improving trial participation in underserved communities at the trail design level, by an equitable implementation of research findings and embedding EDI principles throughout the Centre’s work.

Research lead

Assoc. Prof Ameeta Retzer

Ameeta Retzer is an Associate Professor at the University of Birmingham and a mixed-methods researcher specialising in outcome methodology, health inequalities, public health, and research equity. Funded by the NIHR Birmingham Biomedical Research Centre, Ameeta led the development of a toolkit designed to capture a representative and equitable sample in health research. As the Equity, Diversity, and Inclusion (EDI) lead for several NIHR and charitably-funded regional and national research infrastructures, Ameeta drives the development of inclusive research methods, evaluates health inequalities, and champions public health research. Additionally, her work focuses on patient-reported outcome implementation, methodology, and outcome standardisation, particularly in oncology and brain tumour research, aiming to improve outcomes in both research and routine clinical practice.

University lead

Dr Pauline McCormack - Newcastle University

Dr. Pauline McCormack is a Senior Lecturer at Newcastle University and a medical sociologist with expertise in education, social policy, and participatory methods.

Dr Blánaid Hicks - Queens University Belfast

Dr. Blánaid Hicks is a Senior Lecturer at Queen’s University Belfast and a Queen’s Vice Chancellor’s Fellow and Cancer Research UK Fellow within the Cancer Epidemiology Research Group at the Centre for Public Health.

Area Overview

Advancing equity, diversity, and inclusion in rare disease research and clinical trials.

Rare disease clinical trials often under-represent patients from socioeconomically deprived and ethnic minority groups, leading to disparities in trial access and health outcomes. Barriers to participation include digital poverty, geographical isolation, cultural factors such as consanguinity, and language differences. Addressing these systemic challenges is essential to ensuring that research is inclusive and that all rare disease patients have equitable opportunities to benefit from clinical advancements. 

Our approach will focus on improving trial participation among underserved communities by embedding equality, diversity, and inclusion (EDI) principles throughout the Accelerating Rare Disease Trials (ARDT) programme. This includes designing trials that minimise participation burdens, implementing targeted engagement strategies, and working towards the equitable implementation of research findings. 

By fostering a more inclusive research culture, this work will enhance representation in clinical trials, improve access to innovative treatments, and help ensure that all rare disease patients receive the highest standard of care, regardless of background or circumstances. 

Interested in working with the team?

We are always looking for talented researchers, clinicians, and industry partners to join our efforts in accelerating rare disease trials. Whether you’re interested in research collaboration, clinical trial design, or patient engagement, we’d love to hear from you.